What should I change if I become resistant to dasatinib?

Dasatinib (Dasatinib) is a targeted drug mainly used to treat chronic myelogenous leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). However, as treatment progresses, some patients may develop drug resistance, which affects the effectiveness of the treatment. Therefore, it is particularly important to choose an appropriate alternative treatment after dasatinib resistance.

Resistance may be caused byBCR-ABL gene mutations, overexpression of drug efflux pumps, or activation of other signaling pathways. After understanding the resistance mechanism, subsequent treatment options can be selected more specifically.

In the case of dasatinib resistance, commonly used alternative drugs include imatinib (Imatinib) and nilotinib (Nilotinib). Nilotinib may be an effective option for some patients with resistance due to BCR-ABL mutations. Studies have shown that nilotinib also has better efficacy under specific mutation types (such as T315I mutation). In addition, as a first-generation TKI drug, imatinib has a relatively high incidence of resistance, but for some patients who are resistant to dasatinib, reusing imatinib may still be effective, especially when no new mutations occur.

For those patients who develop theT315I mutation, a common alternative is Bruton's tyrosine kinase inhibitors (such as bosutinib), which have shown strong inhibitory effects on this specific mutation. In clinical practice, due to the different mechanisms of Bruton's tyrosine kinase inhibitors, they are often able to overcome the resistance produced by dasatinib and achieve good therapeutic effects.

At the same time, clinical trials are also an option that cannot be ignored. The development of new drugs is progressing rapidly, and many clinical trials targeting specific mutations or resistance mechanisms are ongoing. Participating in these trials not only provides access to the latest treatment options, but may also provide patients with additional treatment opportunities.